Evidence map›Paper›PMID 37593574›Full record

ArticleRSC medicinal chemistry2023

Design, synthesis, and evaluation of BTK-targeting PROTACs with optimized bioavailability

Yonghui Sun, Zimo Yang, Zhimin Zhang, Zhen Li, Liubin Guo, Hao Pan, Xin Luo, Dongzhou Liu, Yu Rao

Open access · greenAbstract read
In one paragraph

Article in RSC medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. FDA-approved kinase inhibitors in PROTAC design, development and synthesis.Journal of enzyme inhibition and medicinal chemistry · 2025
    Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yonghui SunMOE Key Laboratory of Protein Sciences, School of Pharmaceutical Sciences, MOE Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology, Tsinghua University Beijing 100084 China yrao@tsinghua.edu.cn.ORCID https://orcid.org/0000-0002-0554-5566
Zimo YangMOE Key Laboratory of Protein Sciences, School of Pharmaceutical Sciences, MOE Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology, Tsinghua University Beijing 100084 China yrao@tsinghua.edu.cn.ORCID https://orcid.org/0000-0002-4792-8231
Zhimin ZhangGlobal Drug Development Center, Huadong Medicine Co., Ltd No. 866 Mogan Mountain Road Hangzhou 310011 China jefferydliu@eastchinapharm.com.
Zhen LiMOE Key Laboratory of Protein Sciences, School of Pharmaceutical Sciences, MOE Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology, Tsinghua University Beijing 100084 China yrao@tsinghua.edu.cn.
Liubin GuoGlobal Drug Development Center, Huadong Medicine Co., Ltd No. 866 Mogan Mountain Road Hangzhou 310011 China jefferydliu@eastchinapharm.com.
Hao PanGlobal Drug Development Center, Huadong Medicine Co., Ltd No. 866 Mogan Mountain Road Hangzhou 310011 China jefferydliu@eastchinapharm.com.
Xin LuoMOE Key Laboratory of Protein Sciences, School of Pharmaceutical Sciences, MOE Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology, Tsinghua University Beijing 100084 China yrao@tsinghua.edu.cn.
Dongzhou LiuGlobal Drug Development Center, Huadong Medicine Co., Ltd No. 866 Mogan Mountain Road Hangzhou 310011 China jefferydliu@eastchinapharm.com.
Yu RaoMOE Key Laboratory of Protein Sciences, School of Pharmaceutical Sciences, MOE Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology, Tsinghua University Beijing 100084 China yrao@tsinghua.edu.cn.ORCID https://orcid.org/0000-0002-4356-8531
Tsinghua University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ibrutinib is a first-line drug for the treatment of B-cell malignancies. BTK

Identifiers

PMID37593574
PMCPMC10429852
OpenAlexW4381515045

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.